Dorzolamide
Cosopt, Trusopt (dorzolamide) is a small molecule pharmaceutical. Dorzolamide was first approved as Trusopt on 1994-12-09. It is used to treat open-angle glaucoma in the USA. It is known to target carbonic anhydrase 1, carbonic anhydrase 7, carbonic anhydrase 12, carbonic anhydrase 14, and carbonic anhydrase 4.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
Trade Name
FDA
EMA
Combinations
Cosopt (generic drugs available since 2008-10-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dorzolamide hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRUSOPT | Merck Sharp & Dohme | N-020408 DISCN | 1994-12-09 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cosopt pf | New Drug Application | 2022-11-08 |
| dorzolamide hydrochloride and timolol maleate | ANDA | 2022-06-30 |
| trusopt | New Drug Application | 2020-12-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| open-angle glaucoma | EFO_0004190 | D005902 | H40.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
25 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | 3 | 3 | 3 | — | 8 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 1 | 4 | 2 | — | 7 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 2 | 2 | 1 | — | 5 |
| Bacterial infections | D001424 | A49 | 1 | 1 | — | 1 | — | 3 | |
| Cross infection | D003428 | — | 1 | 1 | 1 | — | 3 | ||
| Healthy volunteers/patients | — | 1 | — | — | 1 | — | 2 | ||
| Infections | D007239 | EFO_0000544 | — | — | 1 | 1 | — | 2 | |
| Febrile neutropenia | D064147 | — | — | — | 1 | — | 1 | ||
| Sepsis | D018805 | A41.9 | — | — | — | 1 | — | 1 | |
| Intraabdominal infections | D059413 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 2 | 1 | — | — | 3 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | — | 3 | — | — | 3 |
| Peritonitis | D010538 | EFO_0008588 | K65 | — | — | 3 | — | — | 3 |
| Abdominal abscess | D018784 | EFO_1001753 | — | 1 | 1 | — | — | 2 | |
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | 2 | — | — | 2 |
| Cholecystitis | D002764 | HP_0001082 | K81 | — | — | 2 | — | — | 2 |
| Bacterial infections and mycoses | D001423 | — | — | 2 | — | — | 2 | ||
| Healthcare-associated pneumonia | D000077299 | — | 1 | 1 | — | — | 1 | ||
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | 1 | 1 | — | — | 1 |
| Community-acquired infections | D017714 | — | — | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Meningitis | D008581 | EFO_0000584 | G03 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DORZOLAMIDE |
| INN | dorzolamide |
| Description | Dorzolamide is 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension. It has a role as an EC 4.2.1.1 (carbonic anhydrase) inhibitor, an antihypertensive agent and an antiglaucoma drug. It is a sulfonamide and a member of thiophenes. |
| Classification | Small molecule |
| Drug class | carbonic anhydrase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21 |
Identifiers
| PDB | 3FW3 |
| CAS-ID | 120279-96-1 |
| RxCUI | 60207 |
| ChEMBL ID | CHEMBL218490 |
| ChEBI ID | 4702 |
| PubChem CID | 5284549 |
| DrugBank | DB00869 |
| UNII ID | 9JDX055TW1 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CA1
CA1
CA7
CA7
CA12
CA12
CA14
CA14
CA4
CA4
Organism
Homo sapiens
Gene name
CA1
Gene synonyms
NCBI Gene ID
Protein name
carbonic anhydrase 1
Protein synonyms
CA-I, CAB, Carbonate dehydratase I, Carbonic anhydrase B, Carbonic anhydrase I, Cyanamide hydratase CA1, epididymis secretory protein Li 11, epididymis secretory sperm binding protein
Uniprot ID
Mouse ortholog
Car1 (12346)
carbonic anhydrase 1 (Q9DC84)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,045 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
701 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more